ZC3H8: A Potential Drug Target and Biomarker (G84524)

Target Name: ZC3H8

NCBI ID: G84524

ZC3H8

ZC3H8: A Potential Drug Target and Biomarker

Zinc finger nucleoside (ZFN) is a type of nucleic acid drug that is widely used in drug screening and gene therapy. ZC3H8 (ZC3HDC8) is a natural ZFN with good biological activity and broad pharmacological properties. This article will review ZC3H8 from the aspects of drug targets, medicinal chemistry and clinical applications, in order to provide useful reference for related research.

1. Drug targets

1. Overview of drug targets

As a ZFN, ZC3H8's drug target is mainly the nucleic acid metabolism process in cells. Specifically, ZC3H8 can inhibit key steps in the nucleic acid biosynthesis process, such as DNA polymerization, RNA synthesis, etc., by binding to specific nucleic acid metabolism enzymes in cells, leading to an imbalance of nucleic acid levels in cells, thereby achieving the purpose of treating diseases.

2. Detailed analysis of drug targets

2.1 DNA polymerase

DNA polymerase is a crucial enzyme in the nucleic acid biosynthesis process and is responsible for synthesizing new DNA strands on DNA templates. ZC3H8 has been shown to specifically bind to DNA polymerase, thereby inhibiting its activity, leading to blockage of DNA biosynthesis. This provides an important theoretical basis for ZC3H8 as a potential anti-tumor drug.

2.2 RNA polymerase

RNA polymerase is the enzyme responsible for transcribing DNA template into RNA during transcription. ZC3H8 also has the ability to inhibit RNA polymerase activity, which makes ZC3H8 have broad clinical application prospects. For example, by inhibiting RNA polymerase activity, ZC3H8 can reduce RNA production in tumor cells, thereby inhibiting their growth and spread.

2.3 Other nucleic acid metabolic enzymes

In addition to DNA and RNA polymerases, ZC3H8 can also combine with other nucleic acid metabolic enzymes, such as phosphodiesterase, RNA splicing enzyme, etc., thereby inhibiting different steps in the nucleic acid biosynthesis process and achieving comprehensive control of nucleic acid metabolism.

2. Medicinal Chemistry

1. Basic information on medicinal chemistry

The chemical name of ZC3H8 is 3-[(3-chloro-4-hydroxyphenyl)amino]-5-azacyclophosphoramide, and its structural formula is as follows:

Cl
|
HNCCCNCCN
|H
|
Cl

2. Medicinal chemical analysis

ZC3H8 is a heterocyclic phosphoramide with the following characteristics:

(1) Good water solubility: ZC3H8 has good solubility in water, which is beneficial to the absorption and distribution of drugs in the body.

(2) Broad pH adaptability: ZC3H8 has good solubility and biological activity in the pH range of 4-8, which is conducive to achieving the therapeutic effect of the drug under different physiological conditions.

(3) High chemical stability: ZC3H8 has good chemical stability and is not easily degraded in both internal and external environments, which is beneficial to the stability of the drug during the treatment process.

(4) Interaction with biomolecules: ZC3H8 has certain lipophilicity and can combine with biomolecules such as proteins and nucleic acids, thereby affecting their biological activity and providing the possibility for targeted delivery of drugs.

3. Clinical application

1. Drug targets and disease treatment

As a drug with a broad range of drug targets, ZC3H8 can provide potential treatments for a variety of diseases. For example, ZC3H8 can inhibit DNA replication in tumor cells by inhibiting DNA polymerase activity, thereby inhibiting tumor growth. At the same time, ZC3H8 can also inhibit the production of RNA in tumor cells by inhibiting RNA polymerase activity, thereby inhibiting the growth and spread of tumor cells.

2. Drug dosage and therapeutic effect

The relationship between drug dosage and therapeutic effect is the focus of drug research. Currently, there is a lack of systematic research on the drug dosage of ZC3H8. However, existing studies have shown that the biological activity of ZC3H8 in vitro and in vivo is directly proportional to its concentration. Therefore, in future studies, the drug therapeutic effect of ZC3H8 can be further improved by controlling the dose of ZC3H8.

4. Conclusion

As a ZFN with good biological activity and extensive pharmacological properties, ZC3H8 provides an important theoretical basis for the research of anti-tumor drugs. ZC3H8 inhibits key steps in the nucleic acid biosynthesis process by binding to specific nucleic acid metabolism enzymes in cells, thereby achieving comprehensive regulation of nucleic acid metabolism. Given that ZC3H8 has a wide range of drug targets and good biological activities, ZC3H8 is expected to become a drug with broad clinical application prospects in future research.

Protein Name: Zinc Finger CCCH-type Containing 8

Functions: Acts as a transcriptional repressor of the GATA3 promoter. Sequence-specific DNA-binding factor that binds to the 5'-AGGTCTC-3' sequence within the negative cis-acting element intronic regulatory region (IRR) of the GATA3 gene (By similarity). Component of the little elongation complex (LEC), a complex required to regulate small nuclear RNA (snRNA) gene transcription by RNA polymerase II and III (PubMed:23932780). Induces thymocyte apoptosis when overexpressed, which may indicate a role in regulation of thymocyte homeostasis

The "ZC3H8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZC3H8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets